Proceedings: Hormones in breast cancer patients on tamoxifen. by Golder, M. P. et al.
246 B.A.C.R. 16TH ANNUAL GENERAL MEETING
TUMOUR INHIBITORY TRIAZENES.
D. E. V. WILMAN, Chester Beatty Research
Institute, London.
5-(3, 3- Dimethyl-l-triazeno) imidazole-4-
carboxamide (DIC) is a well known anti-
tumour agent undergoing clinical trial. It
has the disadvantage of being very photo-
sensitive. The related aryltriazenes, how-
ever, do not decompose in this fashion
although they are acid labile, to an extent
dependent on the ring substituents.
In the case of 1-aryl-3, 3-dialkyltriazenes,
the ring substituents have no marked effect
on the activity towards the TLX5 lymphoma.
Replacement of both methyl groups by ethyl
orisopropyl groups leads to inactivity, where-
as if only one is replaced activity is retained.
Microsomal metabolism experiments suggest
that this is due to enzymic dealkylation to
form the monoalkyl derivative.
Metabolism of I-aryl-3-methyl-3-alkyl-
triazenes gives the monomethyltriazene.
Monomethyltriazenes are more acid labile
and the activity of this metabolite is depen-
dent on its half-life and hence the ring
substituent. The dialkyltriazenes probably
act as a slow release form of the monoalkyl
metabolite, which is the active species.
UPTAKE OF SULPHONAMIDES BY
ANIMAL TUMOURS AND THE ANTI-
TUMOUR PROPERTIES OF TRIA-
ZENES DERIVED FROM THEM. G.
ABEL, Chester Beatty Research Institute,
London.
The distribution of several sulphonamides
in various tissues of the mouse has been
examined. When compared with their con-
centration in the liver, several ofthe sulphon-
amides showed preferential deposition in the
PC6 plasma cell tumour. No correlation was
found between the tumour/liver concen-
tration ratio and pKa, Po or solubility in
phosphate buffer. The corresponding 3,
3-dimethyltriazenes were synthesized and
tested for their anti-tumour activity. Com-
pared with a standard phenyl triazene, 2 of
them had superior anti-tumour properties.
The triazene prepared from sulphadiazine
was labelled (14C) in the aryl moiety and
(3H) in the methyl groups and its tissue
distribution studied. No selective concen-
tration in the tumour was found.
Studies ofthe metabolism ofthe triazenes
suggest that the active metabolite is the
monomethyl analogue which can decompose
chemically into alkylating moieties.
THE ROLE OF ALKALINE PHOS-
PHATASE IN THE RELEASE OF p-
HYDROXY ANILINE MUSTARD FROM
ITS PHOSPHATE CONJUGATE. P.
WORKMAN, J. A. DOUBLE and C. R. BALL,
Department of Cancer Research, University
of Leeds.
Para-hydroxy aniline mustard phosphate
(AM-O-phos) was among the esters of
p-hydroxy aniline mustard (AM-OH) synthes-
ized with the aim that such conjugates would
exhibit a specific cytotoxic effect, via the
release of AM-OH, towards tumours contain-
ing high levels of the appropriate decon-
jugating enzymes (Bukhari, Everett and
Ross, Biochem. Pharmac., 1971, 21, 963).
Subsequently AM-O-phos was showrh to be a
substrate for selected phosphatases (Ball and
Double, Biochem. Pharmac., 1974, 23, 3173).
In this work the cytotoxicity of AM-O-phos
in HeLa cultures was studied in relation to
the phosphatases of this cell line. The
results are consistent with the view that the
uptake of AM-OH is dependent on the
activity of alkaline phosphatase, of the
carcino placental type, located in the plasma
membrane. No such dependence on acid
phosphatase activity was observed. The
cell culture model has also allowed the
importance of extracellular phosphatase
activity to be assessed.
HORMONES IN BREAST CANCER
PATIENTS ON TAMOXIFEN. M. P.
GOLDER, M. E. A. PHILLIPS, M. BAUM, K.
GRIFFITHS, D. R. FAHMY, J. M. HENK, V.
JONES AND P. E. PREECE, South Wales and
Monmouthshire Radiotherapy Centre,
Velindre Hospital, and Tenovus Institute for
Cancer Research, Department of Surgery,
Welsh National School of Medicine, Cardiff.
Tamoxifen (20 mg) has been given twice
daily to 30 consecutive post-menopausal
women with advanced breast cancer. Pro-
lactin, oestradiol 17f, growth, luteinizing and
follicle stimulating hormones have been
assayed on plasma taken before and at
regular intervals during treatment. By the
criteria of Forrest (in Clinical Management of
Advanced Breast Cancer. Eds. Joslin and
Gleave, Cardiff: Alpha Omega Alpha Publish-ABSTRACTS OF MEMBERS PAPERS 247
ing Co. 1970), between 30 and 40% had
objective remissions.
Pre-treatment levels of prolactin were
variable, and were not changed by treatment,
whether or not remission occurred. Pre-
treatment levels of oestradiol varied less, but
were also substantially unchanged in all
patients during treatment. Growth hor-
mone showed no consistent response. In
most patients in whom regression of disease
was observed, values of luteinizing and
follicle stimulating hormone did not vary, but
in the majority ofnon-responders, gonadotro-
phin levels were lowered.
METABOLIC ABNORMALITIES IN
TUMOUR BEARING ANIMALS. K. C.
CALMAN and R. A. McALLISTER, Department
of Clinical Oncology, Western Infirmary,
Glasgow.
Twenty-four hours after implantation of
the TLX-5 lymphoma in CBA mice, the CoA
content of liver was significantly reduced
(P < 0-001). Significant reductions in the
CoA content continued up to the seventh day,
when the animals were in a moribund state.
The citrate content of liver showed no further
significant increases until the seventh day.
Significant reductions in energy content
(ATP, ADP, AMP) of these livers did not
occur until 6 days after implantation.
Control experiments in which normal CBA
mice were challenged with i.p. injections of
normal CBA spleen cells, or with spleen cells
from A strain mice, showed no change in the
CoA or citrate content of liver. No decrease
in CoA was noted in starvation experiments.
These results indicate that serious meta-
bolic abnormalities occur in the non-involved
organs of tumour bearing animals and these
may be related to the development of
cachexia.
UPTAKE OF 67GALLIUM BY NORMAL
LACTATING MAMMARY GLAND AND
BY TUMOURS IN THE DOG. A. T.
YOXALL and L. N. OWEN, Department of
Clinical Veterinary Medicine, University of
Cambridge.
Following intravenous injection of 67Ga
it is known that there is a concentration of
the isotope in several tumours and in a few
normal tumours, including lactating mam-
mary gland. Investigations in the lactating
bitch have shown that 67Ga and 45Ca were
taken up by the mammary tissue at the same
rate and that the isotopes reached similar
levels in both plasma and milk. The isotopes
were found to be associated with calcium
binding proteins in milk. It was not
possible to show any correlation between
67Ga and 45Ca uptake in a transmissible
venereal tumour.
A preliminary study to investigate ifthere
is any association between the " leakiness "
oftumour blood vessels as determined by the
uptake of 1251-albumin and 67Ga in a
melanoma has produced equivocal results.
THE PROGNOSIS FOLLOWING SUR-
GICAL EXCISION OF CANINE MAM-
MARY CARCINOMATA. D. E. Bos-
TOCK, Department of Clinical Veterinary
Medicine, University of Cambridge.
Spontaneously arising canine mammary
carcinomata may be of value as models in
immunotherapeutic trials for breast cancer in
women, but before their full potential can be
exploited their behaviour following surgery
alone must be known.
For this reason, 227 bitches from which
histologically confirmed mammary carcino-
mata had been excised were followed up.
Only 43% of these animals were eventually
destroyed as a result of the original tumour
but the accuracy of the prognosis could be
improved by histologically sub-dividing the
tumours. Papillary and tubular adeno-
carcinomata carried the most favourable
prognosis, the median survival times being 12
and 90 weeks. Dogs with solid carcinomata
had a medial post surgical survival time of44
weeks whereas for those with anaplastic
carcinoma it was only 11 weeks. Clinical
immunotherapeutic trials will thus be con-
centrated on dogs with the latter tumour
types.
Since most dogs die from their tumour
within 12 months of surgery it should be
possible to evaluate the effect ofpost surgical
immunotherapy sooner than would be
possible with a similar trial in man.
AUTORADIOGRAPHY OF EHRLICH
ASCITES TUMOURS TREATED WITH
SOYBEAN TRYPSIN INHIBITOR IN
VIVO. P. WHUR and H. KOPPEL, Cell
Biology Unit, Marie Curie Memorial Found-
ation, Oxted and B. WEATHERHEAD, Depart-